Valuation dashboard for Cogent Biosciences, Inc. (COGT) with P/E N/A, P/B 10.20, EV/EBITDA -15.06 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST).
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $31.02 (closing price, October 30, 2026), COGT has negative trailing earnings (P/E not meaningful) and an ROE of -72.57%. Market capitalisation stands at $5.4B.
Balance sheet quality for COGT: current ratio of 14.2. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 10.20 |
| EV / EBITDA | -15.06 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.31 |
| vs Current Price | -99.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| COGT | Cogent Biosciences, Inc. | $5.4B | 10.20 | -72.6% | |
| INCY | Incyte Corporation | $24.5B | 64.04 | 4.34 | 7.1% |
| IDYA | IDEAYA Biosciences, Inc. | $3.1B | 2.45 | -16.5% | |
| TNGX | Tango Therapeutics, Inc. | $3.8B | 3.32 | -25.7% | |
| NRIX | Nurix Therapeutics, Inc. | $2.9B | 11.60 | 3.09 | 49.3% |
| RCUS | Arcus Biosciences, Inc. | $2.3B | 4.94 | -88.0% |
Price
| Price | $31.02 (closing price, October 30, 2026) |
| Market Cap | $5.4B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -72.57% |
| Return on Invested Capital | -50.09% |
| Return on Assets | -45.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: INCY · IDYA · TNGX · NRIX · RCUS
Explore sector: Healthcare · Biotechnology
More sections of COGT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks